EpilepsyGTx Raises Series A Funding to Advance Gene Therapy Program EPY201

EpilepsyGTx, a UK-based biotechnology company focused on the research and development of innovative gene therapies for the treatment of refractory epilepsy, has announced a Series A financing round to advance its lead program, EPY201, through Phase 1/2a clinical studies. The round was backed by XGEN Venture, a venture capital fund specializing in the life sciences sector, the British Business Bank, and a global biopharmaceutical company.

The funding will support the first-in-human Phase 1/2a clinical trials to assess the safety and efficacy of the company’s lead gene therapy program, EPY201, in a broad population of patients with focal drug-resistant epilepsy (FRE). With future financing rounds, EpilepsyGTx also plans to develop a pipeline of innovative gene therapies targeting drug-resistant epilepsy and neuronal hyperexcitability disorders.

A&O Shearman advised XGEN Venture on the investment round with a cross-border team from the Milan and London offices, led by partner Emanuele Trucco and supported by associates Filippo Linzi and Aabynn Cha.